financetom
Business
financetom
/
Business
/
Mercedes keeps 'value over volume' approach in tough Chinese market
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mercedes keeps 'value over volume' approach in tough Chinese market
Sep 7, 2025 1:42 PM

MUNICH (Reuters) -German luxury automaker Mercedes-Benz is sticking with its premium strategy in its main market China, where a brutal pricing war has cost the group market share as local customers increasingly switch to cheaper domestic models.

CEO Ola Kaellenius, speaking to Reuters ahead of the IAA auto show in Munich, said the new electric GLC SUV - which Mercedes-Benz unveiled on Sunday - would be instrumental in recovering lost ground in the world's largest auto market.

"This is going to hit the nail on the head in terms of what Chinese Mercedes customers are looking for," Kaellenius said.

"And yes, we charge a little bit more. But GLC fans can rest assured ... from a pricing point of view, if you're currently a GLC customer, you will also feel at home with this new electric GLC."

Like Porsche, Mercedes-Benz has been protecting margins at the expense of market share in China, where it suffered a 19% decline in vehicle sales to 140,400 in the second quarter of 2025.

Kaellenius said the company would not change its strategy in China and would maintain its premium approach.

Mercedes-Benz and its European peers are currently awaiting a lowering of U.S. auto import tariffs to 15% from 27.5%, something Washington has pledged as part of the European Union's move to eliminate tariffs on most U.S. goods.

"The European Commission and their trade team are working with the American administration on this," Kaellenius said, adding he hoped that the U.S. administration would soon sign an executive order to get the tariffs down.

Kaellenius did not quantify the financial impact tariffs have had so far on the group's results but said "we're doing what we can to mitigate it".

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TransAlta Enters Automatic Share Purchase Plan With Broker
TransAlta Enters Automatic Share Purchase Plan With Broker
Jun 24, 2024
05:51 PM EDT, 06/24/2024 (MT Newswires) -- TransAlta ( TAC ) said late Monday it entered into an automatic share purchase plan with its broker to facilitate repurchases of common shares under its normal course issuer bid. The company previously received approval from the Toronto Stock Exchange to purchase up to 14 million common shares during a 12-month period through...
Hess CEO to join Goldman Sachs board as independent director
Hess CEO to join Goldman Sachs board as independent director
Jun 24, 2024
NEW YORK, June 24 (Reuters) - John Hess, CEO of Hess Corp ( HES ), has joined the board of Goldman Sachs ( GS ) as independent director, the Wall Street firm said on Monday. He is the latest addition to the board after senior banking executive Tom Montag joined as an independent director last year. He will also become...
Martin Midstream Works With EPA, Others to Contain Spill in Arkansas; Shares Fall After Hours
Martin Midstream Works With EPA, Others to Contain Spill in Arkansas; Shares Fall After Hours
Jun 24, 2024
05:45 PM EDT, 06/24/2024 (MT Newswires) -- Martin Midstream Partners ( MMLP ) said late Monday it is working with the US Environmental Protection Agency, Arkansas Department of Energy and Environment, and Arkansas Game and Fish Commission to respond to a spill of about 2,000 barrels of crude oil. The spill originated from the company's transfer pipeline that connects its...
VTv Therapeutics Announces Screening of First Patient in Trial of Cadisegliatin for Type 1 Diabetes
VTv Therapeutics Announces Screening of First Patient in Trial of Cadisegliatin for Type 1 Diabetes
Jun 24, 2024
05:50 PM EDT, 06/24/2024 (MT Newswires) -- VTv Therapeutics ( VTVT ) said Monday the first patient was screened in a trial of cadisegliatin as an adjunct treatment of type 1 diabetes. The registrational study will form the core of the regulatory submission for cadisegliatin, vTv said. The study will evaluate the safety and efficacy of cadisegliatin over 12 months...
Copyright 2023-2026 - www.financetom.com All Rights Reserved